Summit Therapeutics Ownership | Who Owns Summit Therapeutics?

Overview ForecastFinancials Chart Transcripts

Summit Therapeutics Ownership Summary

Summit Therapeutics is owned by 13.15% institutional investors, 84.30% insiders, and 2.55% retail investors. Baker bros. advisors lp is the largest institutional shareholder, holding 4.54% of SMMT shares. Vanguard US Total Market Shares ETF is the top mutual fund, with 0.46% of its assets in Summit Therapeutics shares.

SMMT Ownership Benchmark

Type	Name	% Inst	% Insiders	% Retail
Stock	Summit Therapeutics	13.15%	84.30%	2.55%
Sector	Healthcare Stocks	488.17%	11.08%	-399.26%
Industry	Biotech Stocks	306.59%	11.10%	-217.69%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

Holder	Shares	% Holding	Value
Baker bros. advisors lp	33.72M	4.54%	$717.62M
Vanguard group	11.67M	1.61%	$208.26M
Blackrock	7.90M	1.13%	$61.61M
Fmr	8.06M	1.11%	$143.75M
Blackrock funding, inc. /de	6.85M	0.92%	$145.70M
Price t rowe associates inc /md/	6.56M	0.90%	$117.00M
State street	4.12M	0.59%	$32.16M
Geode capital management	3.20M	0.44%	$57.13M
Pictet asset management sa	2.16M	0.29%	$45.55M
Charles schwab investment management	1.49M	0.20%	$26.50M

Top Institutional Shareholders by % of Total Assets

Holder	Shares	% Assets	Value
Baker bros. advisors lp	33.72M	6.96%	$717.62M
Cutter capital management, lp	400.00K	3.36%	$7.72M
Polymer capital management (hk)	890.03K	2.86%	$18.94M
Rock springs capital management lp	710.00K	0.94%	$15.11M
Sectoral asset management	65.22K	0.92%	$1.39M
Healthinvest partners ab	92.74K	0.84%	$1.97M
Perseverance asset management	139.93K	0.75%	$2.98M
Jgp global gestao de recursos ltda.	17.08K	0.69%	$304.79M
Qvt financial lp	360.52K	0.68%	$7.67M
Wealth management partners	75.61K	0.60%	$1.71M

Top Buyers

Holder	Shares	% Assets	Change
Baker bros. advisors lp	33.72M	6.96%	9.30M
Price t rowe associates inc /md/	6.56M	0.01%	1.12M
Ubs group	1.19M	0.00%	1.07M
Polar capital	1.00M	0.11%	1.00M
Fiera capital	782.85K	0.06%	782.85K

Top Sellers

Holder	Shares	% Assets	Change
State street	4.12M	0.00%	-3.99M
Blackrock	7.90M	0.00%	-1.92M
Balyasny asset management	-	-	-1.70M
Blackrock funding, inc. /de	6.85M	0.00%	-1.55M
Millennium management	887.01K	0.01%	-1.16M

New Positions

Holder	Shares	% Assets	Change	Value
Polar capital	1.00M	0.11%	1.00M	$21.28M
Fiera capital	782.85K	0.06%	782.85K	$16.66M
Bnp paribas arbitrage, snc	493.19K	0.00%	493.19K	$8.80M
Cutter capital management, lp	400.00K	3.36%	400.00K	$7.72M
Rockland trust	400.00K	0.41%	400.00K	$8.51M

Sold Out

Holder	Change
Citadel advisors	-5.00
Signaturefd	-9.00
Geowealth management	-14.00
Stephens consulting	-20.00
Capital performance advisors llp	-36.00

Institutional Ownership Trends

Date	Holdings	Change %	Shares	Change %	Ownership	Change %	Increased Position	Change %	Decreased Position	Change %
Jun 30, 2025	248	8.30%	97,673,633	-0.07%	13	7.50%	133	17.70%	70	-4.11%
Mar 31, 2025	14	-93.83%	26,286,219	-71.60%	3	2.20%	7	-95.17%	2	-94.74%
Dec 31, 2024	208	9.47%	86,084,916	1.94%	11	8.77%	131	12.93%	39	11.43%
Sep 30, 2024	189	43.18%	84,448,625	17.02%	11	11.18%	115	79.69%	35	-23.91%
Jun 30, 2024	131	23.58%	72,166,501	45.37%	10	16.02%	64	10.34%	45	73.08%

Top Mutual Funds Shareholders

Holder	Shares	% Holding	Change
Vanguard US Total Market Shares ETF	3.43M	0.46%	-167.64K
T. Rowe Price Health Sciences	2.75M	0.37%	-103.45K
Fidelity Growth Compy Commingled Pl S	2.69M	0.36%	103.64K
SPDR® S&P Biotech ETF	2.41M	0.33%	59.51K
Vanguard Total Stock Mkt Idx Inv	2.37M	0.32%	-50.74K
iShares Russell 2000 ETF	2.31M	0.31%	-
Fidelity Growth Company Fund	2.08M	0.28%	81.80K
Vanguard Small Cap Index	1.80M	0.24%	-12.15K
Fidelity Select Biotechnology	1.69M	0.23%	-40.00K
Vanguard Institutional Extnd Mkt Idx Tr	1.52M	0.20%	-660.32K

Recent Insider Transactions

Date	Name	Role	Activity	Value
Mar 27, 2024	Zanganeh Mahkam	Chief Executive Officer	Buy	$127.67K
Mar 27, 2024	Zanganeh Mahkam	Chief Executive Officer	Buy	$74.20K
Mar 26, 2024	Zanganeh Mahkam	Chief Executive Officer	Buy	$112.50K
Mar 27, 2024	Zanganeh Mahkam	Chief Executive Officer	Buy	$96.72K
Mar 26, 2024	Dhingra Ankur	Chief Financial Officer	Buy	$375.00K

Insider Transactions Trends

Date	Buy	Sell
2025 Q2	-	-
2025 Q1	-	-
2024 Q4	-	-
2024 Q3	-	-
2024 Q2	-	-

SMMT Ownership FAQ

Who Owns Summit Therapeutics?

Summit Therapeutics shareholders are primarily institutional investors at 13.15%, followed by 84.30% insiders and 2.55% retail investors. The average institutional ownership in Summit Therapeutics's industry, Biotech Stocks , is 306.59%, which Summit Therapeutics falls below.

Who owns the most shares of Summit Therapeutics?

Summit Therapeutics’s largest shareholders are Baker bros. advisors lp (33.72M shares, 4.54%), Vanguard group (11.67M shares, 1.61%), and Blackrock (7.9M shares, 1.13%). Together, they hold 7.27% of Summit Therapeutics’s total shares outstanding.

Does Blackrock own Summit Therapeutics?

Yes, BlackRock owns 1.13% of Summit Therapeutics, totaling 7.9M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 61.61M$. In the last quarter, BlackRock decreased its holdings by -1.925M shares, a -19.59% change.

Who is Summit Therapeutics’s biggest shareholder by percentage of total assets invested?

Baker bros. advisors lp is Summit Therapeutics’s biggest shareholder by percentage of total assets invested, with 6.96% of its assets in 33.72M Summit Therapeutics shares, valued at 717.62M$.

Who is the top mutual fund holder of Summit Therapeutics shares?

Vanguard US Total Market Shares ETF is the top mutual fund holder of Summit Therapeutics shares, with 0.46% of its total shares outstanding invested in 3.43M Summit Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis

Discover trending investment themes
Find your next best investment
Research stocks using tools